var data={"title":"Hydralazine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hydralazine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6319?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hydralazine-drug-information\" class=\"drug drug_general\">see &quot;Hydralazine: Drug information&quot;</a> and <a href=\"topic.htm?path=hydralazine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hydralazine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179464\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apresoline</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053190\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vasodilator</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30151123\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Individualize dose; titrate to patient response. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart failure, afterload reduction:</b> Limited data available: <b>Note</b>: May cause reflex tachycardia; use in combination with beta-blocker therapy has been suggested (Park 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 0.1 to 0.5 mg/kg/dose every 6 to 8 hours; maximum dose: 2 mg/kg/dose (Artman 1987; Cloherty 2012; Friedman 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 0.25 to 1 mg/kg/dose every 6 to 8 hours; maximum daily dose: 7 mg/kg/<b>day</b> (Artman 1987; Cloherty 2012; Friedman 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b>  Limited data available:  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 0.1 to 0.5 mg/kg/dose every 6 to 8 hours; maximum dose: 2 mg/kg/dose every 6 hours (Cloherty 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hypertensive urgency/emergency:</i> 0.15 to 0.6 mg/kg/dose every 4 hours (Flynn 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 0.25 to 1 mg/kg/dose every 6 to 8 hours; maximum daily dose: 7.5 mg/kg/<b>day</b> (Flynn 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053182\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=hydralazine-drug-information\" class=\"drug drug_general\">see &quot;Hydralazine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Individualize dose; titrate to patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heart failure, afterload reduction:</b> Limited data available (Artman 1987, Friedman 1985, Park 2014): <b>Note:</b> May cause reflex tachycardia; use in combination with beta-blocker therapy has been suggested (Park, 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: 0.1 to 0.5 mg/kg/dose every 6 to 8 hours; maximum dose: 2 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: 0.15 to 0.2 mg/kg/dose every 4 to 6 hours; maximum dose: 20 mg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Infants, Children, and Adolescents: 0.75 to 3 mg/kg/day divided every 6 to 12 hours; maximum daily dose: 7 mg/kg/<b>day</b> or 200 mg/<b>day</b> whichever is less</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension, chronic:</b> Children and Adolescents: Oral: Initial: 0.75 mg/kg/day in 2 to 4 divided doses, maximum initial dose: 10 mg/dose; may increase gradually over 3 to 4 weeks up to a maximum of 7.5 mg/kg/day in 2 to 4 divided doses not to exceed 200 mg/<b>day</b> (NHBPEP 2004; NHLBI 2012; Park 2014) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertensive emergency/urgency:</b> Infants, Children, and Adolescents: IM, IV: Initial: 0.1 to 0.2 mg/kg/<b>dose</b> every 4 to 6 hours; increase as required to suggested usual range: 0.2 to 0.6 mg/kg/<b>dose</b> every 4 to 6 hours as needed; maximum dose: 20 mg/dose (NHBPEP 2004; Park 2014; Thomas 2011); manufacturer labeling suggests a dose range of 1.7 to 3.5 mg/kg/day divided in 4 to 6 doses </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b> Oral: Initial: 10 mg 4 times daily for the first 2 to 4 days; increase to 25 mg 4 times daily for the balance of the first week; further increase by 10 to 25 mg/dose gradually (every 2 to 5 days) to 50 mg 4 times daily (maximum: 300 mg daily in divided doses)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertensive emergency:</b> <b>Note:</b> Use is generally not recommended due to unpredictable and prolonged antihypertensive effects (Marik 2007): IM, IV: 10 to 20 mg/dose every 4 to 6 hours as needed (Rhoney 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertensive emergency in pregnancy (systolic BP &ge;160 mm Hg or diastolic BP &ge;110 mm Hg):</b> IM, IV: Initial: 5 or 10 mg; may repeat dose in 20 to 40 minutes with 5 to 10 mg if blood pressure continues to exceed thresholds (ACOG 2015; Magee 2014; Too 2013). Also refer to administration protocols developed by the American College of Obstetricians and Gynecologists (ACOG 2015). A maximum total cumulative dose of 20 mg (IV) or 30 mg (IM) is recommended (Magee 2014). <b>Note:</b> After the initial dose, may initiate a continuous infusion of 0.5 to 10 mg/hour instead of intermittent dosing (Magee 2014).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment  in renal impairment:  </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff 2007). <b>Note:</b> Renally adjusted dose recommendations are based on doses: Oral: 0.75 to 1 mg/kg/day divided every 6 to 12 hours; maximum daily dose: 200 mg/day; IV: 0.1 to 0.2 mg/kg/<b>dose</b> every 6 hours; maximum dose: 20 mg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer every 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: Administer every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): Administer every 12 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): Administer every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 50 mL/minute: Administer every 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Administer every 8 to 16 hours in fast acetylators and every 12 to 24 hours in slow acetylators </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis effects: Supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis effects: Supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment  in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, hydralazine undergoes extensive hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179437\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 25 mg, 50 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179422\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053194\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Administer undiluted as IM injection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Administer undiluted (20 mg/mL) as slow IV push over 1 to 2 minutes (Artman 1984; Beekman 1982); maximum rate: 5 mg/minute (Klaus 1989) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179457\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Store at 15&ordm;C to 30&ordm;C (59&ordm;F to 86&ordm;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at 20&ordm;C to 25&ordm;C (68&ordm;F to 77&ordm;F); use immediately after vial is opened. Solution may discolor upon contact with metal; discard discolored solutions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053193\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment of essential hypertension (FDA approved in pediatric patient [age not specified] and adults); has also been used in heart failure to reduce afterload </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Management of severe essential hypertension when oral therapy not possible or when urgent reduction in blood pressure needed (FDA approved in pediatric patients [age not specified] and adults); has also been used  in heart failure to reduce afterload and hypertension secondary to preeclampsia/eclampsia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179508\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">HydrALAZINE may be confused with hydrOXYzine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Vasodilators (hydralazine) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older with a history of syncope due to its potential to exacerbate episodes of syncope (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179505\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, circulatory shock, flushing, orthostatic hypotension, palpitations, paradoxical pressor response, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, chills, depression, disorientation, dizziness, headache, increased intracranial pressure (IV; in patient with pre-existing increased intracranial pressure), peripheral neuritis, psychotic reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, constipation, diarrhea, nausea, paralytic ileus, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysuria, impotence </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, decreased hemoglobin, decreased red blood cells, eosinophilia, hemolytic anemia, leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Lupus-like syndrome (dose related; fever, arthralgia, splenomegaly, lymphadenopathy, asthenia, myalgia, malaise, pleuritic chest pain, edema, positive ANA, positive LE cells, maculopapular facial rash, positive direct Coombs' test, pericarditis, pericardial tamponade), muscle cramps, rheumatoid arthritis, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis, lacrimation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, nasal congestion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Thrombocytopenia (IV)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179444\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to hydralazine or any component of the formulation; coronary artery disease; mitral valve rheumatic heart disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179426\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-induced lupus-like syndrome: May cause a drug-induced lupus-like syndrome including glomerulonephritis, especially in patients receiving higher doses. If this syndrome occurs, discontinue therapy unless the benefit-to-risk requires continued therapy. Signs and symptoms usually regress after discontinuation of therapy, but residua have been detected many years later. Long-term treatment with steroids may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic effects: Blood dyscrasias (eg, reduction in hemoglobin and red blood cell count, leukopenia, agranulocytosis, purpura) may occur; discontinue therapy if these hematologic effects occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypotension: Postural hypotension may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peripheral neuritis: Hydralazine has been associated with peripheral neuritis (eg, paresthesia, numbness, and tingling), possibly due to an antipyridoxine effect. Pyridoxine therapy should be initiated with onset of such symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use is contraindicated in patients with coronary artery disease (CAD). Use with caution in patients with cerebral vascular accidents and suspected CAD; myocardial stimulation produced by hydralazine can cause anginal attacks and electrocardiogram (ECG) changes of myocardial ischemia; has been implicated in the production of myocardial infarction. According to the American Heart Association/American College of Cardiology/American Society of Hypertension 2015 scientific statement for the treatment of hypertension in patients with CAD, hydralazine (without a concomitant nitrate [eg, isosorbide dinitrate]) should be avoided for the treatment of hypertension in patients with heart failure (with reduced ejection fraction) of ischemic origin (AHA/ACC/ASH [Rosendorff, 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Mitral valvular disease: Use with caution in patients with mitral valvular disease; may increase pulmonary artery pressure in these patients. Use is contraindicated in patients with mitral valve rheumatic heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with advanced renal impairment; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage forms related issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tartrazine sensitivity: May contain tartrazine, which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of tartrazine sensitivity in the general population is low, it is frequently seen in patients who are also hypersensitive to aspirin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179495\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179431\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13356&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of HydrALAZINE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of HydrALAZINE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179460\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food enhances bioavailability of hydralazine. Management: Administer without regard to food, but keep consistent.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179433\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179446\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Hydralazine crosses the placenta (Liedholm, 1982). Intravenous hydralazine is recommended for use in the management of acute onset, severe hypertension (systolic BP &ge;160 mm Hg or diastolic BP &ge;110 mm Hg) with preeclampsia or eclampsia in pregnant and postpartum women. Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother. If treatment for chronic hypertension in pregnancy is needed, other oral agents are preferred as initial therapy (ACOG, 2013; Magee, 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053189\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure (monitor closely with IV use), standing and sitting/supine, heart rate, ANA titer </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179425\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Direct vasodilation of arterioles (with little effect on veins) with decreased systemic resistance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179443\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IV: 10 to 80 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: IM, IV: Up to 12 hours (Marik 2007); <b>Note:</b> Duration may vary depending on acetylator status of patient. Hypotension due to hydralazine may last longer even though the circulating half-life is much shorter (Marik, 2007; O&rsquo;Malley, 1975). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapidly absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 87% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatically acetylated; extensive first-pass effect (oral) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Increased with food </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 3 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179442\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>4 mg/mL Oral Suspension (ASHP standard concentration)</b> (ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 4 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Sweet SF and Ora-Plus. Crush four 100 mg tablets in a mortar and reduce to a fine powder. Add 15 mL of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label &ldquo;shake well&rdquo;, &ldquo;protect from light&rdquo;, &ldquo;store in a refrigerator.&rdquo; Stable for 2 days when stored in amber plastic prescription bottles in the dark and refrigerated (Allen 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Stability reduced to 24 hours if Ora-Sweet is substituted for Ora-Sweet SF.</p>\n    <div class=\"reference\">Allen LV Jr, Erickson MA 3rd. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. <i>Am J Health-Syst Pharm</i>. 1998;55(18):1915-1920.<span class=\"pubmed-id\">9784772</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524631\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (HydrALAZINE HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/mL (1 mL): $5.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (HydrALAZINE HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $41.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $50.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $56.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $101.28</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F179449\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ademan (TW);</li>\n      <li>Alphapress (AU);</li>\n      <li>Aprelazine (TW);</li>\n      <li>Apresol (IN);</li>\n      <li>Apresolin (NO, SE);</li>\n      <li>Apresolina (MX, PT, UY, VE);</li>\n      <li>Apresoline (AU, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GB, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, NZ, PH, QA, SA, SC, SD, SG, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, ZM, ZW);</li>\n      <li>Aprezin (TW);</li>\n      <li>Apulon (TW);</li>\n      <li>Cesoline Y (TH);</li>\n      <li>Cesoline-W (TH);</li>\n      <li>Hidral (AR, UY);</li>\n      <li>Hydrapres (AR, ES);</li>\n      <li>Hylazine (PH);</li>\n      <li>Hyperphen (ZA);</li>\n      <li>Hyperphen-50 (ZW);</li>\n      <li>Hyperzine (PH);</li>\n      <li>Slow-Apresoline (AE, BB, BF, BJ, BM, BS, BZ, CI, EG, ET, GH, GM, GN, GY, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PR, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);</li>\n      <li>Stable (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Committee opinion no. 623: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. <i>Obstet Gynecol</i>. 2015;125(2):521-525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/25611642 /pubmed\" target=\"_blank\" id=\"25611642 \">25611642 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynceol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Artman M, Graham TP Jr. Guidelines for vasodilator therapy of congestive heart failure in infants and children. <i>Am Heart J</i>. 1987;113(4):994-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/3031972 /pubmed\" target=\"_blank\" id=\"3031972 \">3031972 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Artman M, Parrish MD, Boerth RC, Boucek RJ Jr, Graham TP Jr. Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects. <i>Circulation</i>. 1984;69(5):949-954. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/6705171 /pubmed\" target=\"_blank\" id=\"6705171 \">6705171 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beekman RH, Rocchini AP, Rosenthal A. Hemodynamic effects of hydralazine in infants with a large ventricular septal defect. <i>Circulation</i>. 1982;65(3):523-528.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/6459891 /pubmed\" target=\"_blank\" id=\"6459891 \">6459891 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn JT. Neonatal hypertension: diagnosis and management. <i>Pediatr Nephrol</i>. 2000;14(4):332-341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/10775081 /pubmed\" target=\"_blank\" id=\"10775081 \">10775081 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman WF, George BL. Treatment of congestive heart failure by altering loading conditions of the heart. <i>J Pediatr</i>. 1985;106(5):697-706. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/3923176 /pubmed\" target=\"_blank\" id=\"3923176 \">3923176 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hydralazine injection [prescribing information]. Lake Forest, IL: Akorn Inc; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hydralazine tablets [prescribing information]. Lambertville, NJ: Strides Pharma Inc; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients.<i> J Pharm Technol</i>. 1989;5(3):101-128. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/10318297 /pubmed\" target=\"_blank\" id=\"10318297 \">10318297 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liedholm H, W&aring;hlin-Boll E, Hanson A, et al, &quot;Transplacental Passage and Breast Milk Concentrations of Hydralazine,&quot; <i>Eur J Clin Pharmacol</i>, 1982, 21(5):417-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/7200428/pubmed\" target=\"_blank\" id=\"7200428\">7200428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. <i>J Obstet Gynaecol Can</i>. 2014;36(5):416-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/24927294 /pubmed\" target=\"_blank\" id=\"24927294 \">24927294 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE and Varon J, &ldquo;Hypertensive Crises: Challenges and Management,&rdquo; <i>Chest</i>, 2007, 131(6); 1949-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/17565029/pubmed\" target=\"_blank\" id=\"17565029\">17565029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute. Expert panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines. 2012. National Institutes of Health. Available at  <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2004;114(2 Suppl 4th Report):555-576. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/15286277 /pubmed\" target=\"_blank\" id=\"15286277 \">15286277 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhoney D, Peacock WF. Intravenous therapy for hypertensive emergencies, part 1. <i>Am J Health Syst Pharm</i>. 2009;66(15):1343-1352.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/19635770/pubmed\" target=\"_blank\" id=\"19635770\">19635770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas CA. Drug treatment of hypertensive crisis in children. <i>Paediatr Drugs</i>. 2011;13(5):281-290.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/21888442 /pubmed\" target=\"_blank\" id=\"21888442 \">21888442 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Too GT, Hill JB. Hypertensive crisis during pregnancy and postpartum period. <i>Semin Perinatol</i>. 2013;37(4):280-287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydralazine-pediatric-drug-information/abstract-text/23916027/pubmed\" target=\"_blank\" id=\"23916027\">23916027</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13356 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F179464\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053190\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F30151123\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053182\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F179437\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F179422\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053194\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F179457\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053193\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F179508\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F179505\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F179444\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F179426\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F179495\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F179431\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F179460\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F179433\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F179446\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053189\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F179425\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F179443\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F179442\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524631\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F179449\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13356|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hydralazine-drug-information\" class=\"drug drug_general\">Hydralazine: Drug information</a></li><li><a href=\"topic.htm?path=hydralazine-patient-drug-information\" class=\"drug drug_patient\">Hydralazine: Patient drug information</a></li></ul></div></div>","javascript":null}